TW202120560A - 重組多肽及其用途 - Google Patents

重組多肽及其用途 Download PDF

Info

Publication number
TW202120560A
TW202120560A TW109127764A TW109127764A TW202120560A TW 202120560 A TW202120560 A TW 202120560A TW 109127764 A TW109127764 A TW 109127764A TW 109127764 A TW109127764 A TW 109127764A TW 202120560 A TW202120560 A TW 202120560A
Authority
TW
Taiwan
Prior art keywords
cancer
polypeptide
present disclosure
tag
recombinant polypeptide
Prior art date
Application number
TW109127764A
Other languages
English (en)
Chinese (zh)
Inventor
藍耿立
蔡政良
許斐婷
Original Assignee
國立陽明大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立陽明大學 filed Critical 國立陽明大學
Publication of TW202120560A publication Critical patent/TW202120560A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109127764A 2019-08-16 2020-08-14 重組多肽及其用途 TW202120560A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962887674P 2019-08-16 2019-08-16
US62887674 2019-08-16

Publications (1)

Publication Number Publication Date
TW202120560A true TW202120560A (zh) 2021-06-01

Family

ID=74659894

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109127764A TW202120560A (zh) 2019-08-16 2020-08-14 重組多肽及其用途

Country Status (2)

Country Link
TW (1) TW202120560A (fr)
WO (1) WO2021031998A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101492508A (zh) * 2009-01-24 2009-07-29 温州医学院 链亲和素/白细胞介素15融合蛋白
US9856314B2 (en) * 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
CN113603788A (zh) * 2014-01-15 2021-11-05 卡德门企业有限公司 免疫调节剂
CA3012764A1 (fr) * 2016-01-29 2017-08-03 Vedantra Pharmaceuticals, Inc. Polypeptides alk et leurs procedes d'utilisation
AU2018220516A1 (en) * 2017-02-16 2019-09-19 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins

Also Published As

Publication number Publication date
WO2021031998A1 (fr) 2021-02-25

Similar Documents

Publication Publication Date Title
JP6656349B2 (ja) 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
Fiegle et al. Dual CTLA-4 and PD-L1 blockade inhibits tumor growth and liver metastasis in a highly aggressive orthotopic mouse model of colon cancer
US20210169955A1 (en) Use of Oncolytic Herpes Simplex Virus, Alone or in Combination with Immune Check-Point Inhibitor, in the Treatment of Cancer
ES2740358T3 (es) Método de supervisión del tratamiento del cáncer con agonistas de OX40
US10016480B2 (en) Peptide-based methods for treating pancreatic cancer
ES2824120T3 (es) Procedimientos de tratamiento del cáncer usando inhibidores de b-raf e inhibidores de los puntos de control inmunitario
US20220111069A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
JP2017530130A (ja) 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用
JP2022525223A (ja) ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療
JP2021515032A (ja) 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置
TWI728400B (zh) Cd226促效劑抗體
JP7193590B2 (ja) Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
JP2015518835A (ja) 癌幹細胞を標的とした癌ワクチン
US10155024B2 (en) Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells
US20200353050A1 (en) Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
CN110831629B (zh) 用于治疗癌症的包括abx196的组合
TWI817958B (zh) 用於治療肝癌之組合物及方法
TW202120560A (zh) 重組多肽及其用途
WO2022040341A1 (fr) Thérapie abscopale contre le cancer
EP3076988B1 (fr) Compositions pharmaceutiques et méthodes destinées au traitement et à la prévention du cancer métastatique
Umemura et al. A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection
WO2024011946A1 (fr) Dimères polypeptidiques pour le traitement de la sclérose systémique
US20230040928A1 (en) Antibodies having specificity to her4 and uses thereof
US20230085602A1 (en) Pdac treatment regimen
JP7300186B2 (ja) 薬物送達用担体